Shock Wave Therapy Tested for Heart Blood Vessel Growth in Coronary Artery Disease
Tests shock wave therapy on the heart in adults with narrowed coronary arteries.
Plain-language title generated from the registry record
Registry title: Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronary Artery Disease: Validation by Quantitative Cardiac MRI Perfusion
Key facts
- Where
- Hong Kong, Hong KongSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07068399, who can take part
Where in Hong Kong
- HKU Li Ka Shing Faculty of MedicineHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Hong Kong
- Trial code
- NCT07068399
- Record updated
- 9 November 2026
- Original description
This is a randomised controlled trial aimed to demonstrate the effect of cardiac extracorporeal shock wave therapy (CSWT) on the angiogenesis effect of myocardium by determining myocardial perfusion and left ventricular function in patients with coronary artery disease (CAD) when measured by cardiac MRI before and after the treatment.Read full original descriptionShow less
Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronary Artery Disease: Validation by Quantitative Cardiac MRI Perfusion
This is a randomised controlled trial aimed to demonstrate the effect of cardiac extracorporeal shock wave therapy (CSWT) on the angiogenesis effect of myocardium by determining myocardial perfusion and left ventricular function in patients with coronary artery disease (CAD) when measured by cardiac MRI before and after the treatment.
Inclusion: Patients with symptoms of coronary artery disease; Patients without obstructive coronary artery disease; with LVEF not < 40%.
Exclusion: Recent myocardial infarction within 6 months; Contraindication to contrast enhanced stress Cardiac Magnetic Resonance (eg. Estimated GFR <30ml/min/1.73m2, severe allergy to gadolinium based contrast agent, contraindication to adenosine); Age < 18 years,; Pregnancy or lactation; Life expectancy <24 months; Haemodynamically unstable; Participation in other clinical trial within 6 months of enrollment; Unable to consent to or perform components of the study.